J Retin.  2021 Nov;6(2):145-149. 10.21561/jor.2021.6.2.145.

Short-term Efficacy of Brolucizumab Injection for Neovascular Age-related Macular Degeneration with Limited Response to Aflibercept

• Kim JH

• KMID: 2552182
• DOI: http://doi.org/10.21561/jor.2021.6.2.145

Abstract

Purpose
To evaluate short-term efficacy of brolucizumab injection for neovascular age-related macular degeneration (nAMD) refractory to aflibercept.
Case summary
A 66-year-old woman was diagnosed with nAMD and treated with aflibercept. At diagnosis, visual acuity was 0.2 and central retinal thickness (CRT) was 485 µm. After three injections of aflibercept, retinal edema was resolved. However, 3 months after the last injection, recurrence was noted. The patient was treated with aflibercept or bevacizumab for 20 months. However, intraretinal edema was not resolved despite treatment. The patient was switched to brolucizumab, at which time, visual acuity was 0.2 and CRT was 424 µm. Two weeks after switching to brolucizumab, intraretinal fluid was decreased markedly with CRT reduced to 348 µm and visual acuity improved to 0.3. Four weeks after switching, CRT was maintained at 354 µm. No complication, such as intraocular inflammation or occlusive retinal vasculitis, was noted.
Conclusions
Switching to brolucizumab was found to be beneficial in reducing retinal thickness in nAMD refractory to aflibercept.

Keyword

Aflibercept; Age related macular degeneration; Brolucizumab; Choroidal neovascularization